About CARB-X
Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
Investment Details
Investment Range
Not specified
Investment Stage
Various stages
Industry Focus
VR/AR
Investor Type
Accelerator
Investment Focus
Focus Areas